In 2018, the ADA/EASD published a consensus report for the management of hyperglycaemia in type 2 diabetes (https://link. springer.com/article/10.1007/s00125-018-4729-5). Patientcentred care that was focused on reducing the burden of complications represented a paradigm shift in the approach to diabetes management, with the preferred use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors in those with established atherosclerotic cardiovascular disease (ASCVD). Since then, there has been an unprecedented release of new outcome data, mandating a brief update to the 2018 consensus. In this issue, the ADA/EASD (https://doi.org/10.1007/s00125-019-05039w) present important changes to the 2018 consensus, including consideration of GLP-1 RAs and SGLT2 inhibitors for beneficial cardiorenal outcomes in individuals with type 2 diabetes, independently of HbA 1c levels. Where major adverse cardiovascular events are the gravest threat, the evidence favours the preferred use of GLP-1 RAs; as well as being used in those with type 2 diabetes and established ASCVD, their use should be considered in those with specific indicators of high cardiovascular risk. When it comes to the use of SGLT-2 inhibitors in type 2 diabetes, the evidence is now much clearer for their benefit, particularly in those with heart failure with reduced ejection fraction and in those with chronic kidney disease (CKD), and in the prevention of CKD progression. Thus, SGLT-2 inhibitors are preferred for diabetes management in individuals with these comorbidities.
Positioning time in range in diabetes management

Andrew Advani
The time in range (TIR) metric has emerged as being a key indicator of the quality of glucose control in diabetes. In this issue, Andrew Advani (https://doi.org/10.1007/ s00125-019-05027-0) summarises recent TIR research with the aim of assisting healthcare professionals and individuals living with diabetes in interpreting TIR data and setting TIR goals. Evidence is beginning to emerge linking reduced TIR with increased risk of long-term diabetes complications and adverse pregnancy outcomes. This association may be expected given the inverse correlation between TIR and HbA 1c levels. The author explains that, because of the skewed distribution of glucose levels outside the target range, TIR (on its own) is a poor indicator of the frequency and severity of hypoglycaemia. Thus, all TIR discussions should separately consider time below range and, by inference, time above range. In this review, the recent consensus recommendations for time in ranges goals are summarised, although, as is always the case, glycaemic targets should be individualised.
The figures from this review are available as a downloadable slideset.
Competition for publication in Diabetologia continues to grow, and less than 20% of papers are accepted. Of all the high-quality papers that appear in this month's issue I want to draw your attention to five articles that I think are particularly interesting. The articles are summarised here. Our publisher, Springer, has kindly made the full text of each of these papers freely available. I hope you enjoy reading them! Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality Martijn C. G. J. Brouwers, Nynke Simons, Coen D. A.
Stehouwer, Aaron Isaacs
Non-alcoholic fatty liver disease (NAFLD) has emerged as a risk factor for type 2 diabetes and cardiovascular disease (CVD). In this issue, Brouwers and colleagues (https://doi. org/10.1007/s00125-019-05024-3) elaborate on potential mediators of the relationship between NAFLD and CVD, such as plasma lipids, low-grade inflammation, impaired fibrinolysis and hepatokines. By summarising recent advances in genetic studies that focused on the relationship between NAFLD susceptibility genes (PNPLA3, TM6SF2, GCKR and MBOAT7) and CVD, it appears that plasma lipids are an important mediator of that relationship. This has therapeutic implications, particularly for the design of anti-NAFLD drugs that affect lipid metabolism. Since these agents are aimed primarily at preventing end-stage liver disease, it is important to underscore the fact that the principal cause of death in individuals with NAFLD is CVD.
Stearoyl CoA desaturase is a gatekeeper that protects human beta cells against lipotoxicity and maintains their identity
